$VSH — The Market Bought Vishay As An MLCC Stock, Then Sold It As One. It Is Neither.

The multilayer ceramic capacitor shortage is the most legible bottleneck story in the AI trade right now, and it is real. Murata took prices up 15–35%. Yageo went across the board at roughly 50% on July 1. High-capacity parts on the Shenzhen spot market ran 3–5× in a single month.

$VSH rose 192% into mid-June on that story, then gave back more than half of it. Both legs rested on a misreading. Capacitors are 16.5% of Vishay's revenue and ceramic is a slice of that slice — so the name was never the MLCC pure-play the buyers thought they had. But the sell-off was the worse error: the pricing umbrella has since spread to chip resistors and tantalum, which is 41% of Vishay's book, and the architecture shift that spooked everyone consumes the inductors Vishay also makes.

$VSH is a broad passive-and-discrete manufacturer sitting at a genuine margin trough — a 1.9% operating margin in FY25 against 17.6% in FY22 — with a book-to-bill of 1.34 and a backlog that grew 21% in a quarter to $1.6B. The market has spent four months arguing about which capacitor Vishay sells. That is the wrong argument.

But the sell-off inverted the same error. The umbrella that started over ceramic has spread to exactly the products Vishay is largest in. Vishay is a top-tier global resistor maker; resistors alone are 24.7% of revenue, and Walsin and Yageo have both been raising chip-resistor prices since February. Add capacitors and inductors and 53% of the company sits under an industry pricing move.

And the argument that triggered the de-rating is, on its own terms, a reason to own the inductor line: trans-inductor voltage regulators are inductor-intensive. Management is already selling into it — the Q1 call named polymer tantalum capacitors, current-sense resistors and custom magnetics as the specific parts going into AI power management, alongside high-voltage MOSFETs.

Start with what the market actually pays. At $33.79 on 137M diluted shares with $504M of net debt, the enterprise is $5.13B against trailing EBITDA of $312M — 16.5×. That is a multiple on the worst EBITDA Vishay has produced in a decade.

FY22 through FY25 are computed from SEC filings — operating income plus reported depreciation and amortisation. FY26E and FY27E are our own estimates; Vishay guides revenue and gross margin, never EBITDA. The line that matters is this: revenue in FY26 is tracking above the FY22 peak while EBITDA runs at 40% of the FY22 level. The volume is already back. Only the margin has to follow.

The house position is the $60 January 2027 call at $3.30 mid — bid $3.10, ask $3.50, delta 0.31, open interest 307.

The option is not expensive, and this is where the reflex about triple-digit implied volatility gets it wrong. Implied vol on the contract is 99.6%. Realized vol on $VSH is 102.3% over the last 20 sessions, 96.2% over 30 and 97.9% over 60. You are paying roughly one times realized — fair, not rich. Twenty-eight of the last sixty sessions moved more than 5%, and the six largest single-day moves of the past year run +14.5%, −14.1%, +12.8%, +12.0%, −12.0% and +11.6%. A stock that moves like this is priced correctly at parity to its own realized vol, and the buyer of convexity is not overpaying.

At 99.6% volatility over 169 days, the risk-neutral probability of finishing above the strike is roughly 12%. That is the whole trade, stated cleanly — not "does it need +87%" but "is one-in-eight too cheap for a company whose revenue is already back at its 2022 peak, whose product is on allocation across the industry, and which printed $69.47 six weeks ago." Weighting the cases at 35 / 45 / 20 puts fair value near $49 and puts materially more than 12% of the distribution above the strike.

Two earnings events sit inside the trade — August 5 and the Q3 print in early November — plus whatever the next Yageo and Murata pricing rounds do to the complex. The risk needs no dressing up: below $60 in January the contract is worth nothing, and the $63.30 breakeven asks for the June high back. That is the price of buying convexity on a $3.30 outlay instead of paying for delta. Size it as the asymmetric bet it is, alongside the equity rather than instead of it.